BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35137467)

  • 21. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation in the MELD era: a single-center experience.
    Sachdev M; Hernandez JL; Sharma P; Douglas DD; Byrne T; Harrison ME; Mulligan D; Moss A; Reddy K; Vargas HE; Rakela J; Balan V
    Dig Dis Sci; 2006 Jun; 51(6):1070-8. PubMed ID: 16865573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HCC patients suffer less from geographic differences in organ availability.
    Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
    Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Racial-ethnic differences in liver transplant waitlist outcomes in patients with hepatocellular carcinoma before and after recent changes to allocation policy.
    Mazur RD; Cron DC; Goldberg DS; Yeh H; Dageforde LA
    Clin Transplant; 2024 Jun; 38(6):e15365. PubMed ID: 38804605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Projected outcomes of 6-month delay in exception points versus an equivalent Model for End-Stage Liver Disease score for hepatocellular carcinoma liver transplant candidates.
    Alver SK; Lorenz DJ; Marvin MR; Brock GN
    Liver Transpl; 2016 Oct; 22(10):1343-55. PubMed ID: 27343202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form.
    Mehta N; Dodge JL; Roberts JP; Hirose R; Yao FY
    Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28881064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing liver transplant prioritization for hepatocellular carcinoma through risk stratification.
    Norman J; Mehta N; Kwong A
    Curr Opin Organ Transplant; 2023 Aug; 28(4):265-270. PubMed ID: 37339511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.
    Freitas AC; Itikawa WM; Kurogi AS; Stadnik LG; Parolin MB; Coelho JC
    Arq Gastroenterol; 2010; 47(3):233-7. PubMed ID: 21140081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.
    Sharma P; Harper AM; Hernandez JL; Heffron T; Mulligan DC; Wiesner RH; Balan V
    Am J Transplant; 2006 Aug; 6(8):1957-62. PubMed ID: 16771808
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Region 11 MELD Na exception prospective study.
    Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
    Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions.
    Schmitt TM; Kumer SC; Shah N; Argo CK; Northup PG
    Ann Hepatol; 2010; 9(4):390-6. PubMed ID: 21057157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ Sharing.
    Brock GN; Washburn K; Marvin MR
    PLoS One; 2019; 14(10):e0223053. PubMed ID: 31581270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.